Stemtech Corporation Announces Exclusive Taiwan Distribution Licensing Agreement
Stemtech Corporation (OTC: STEK) announced an exclusive distribution licensing agreement with Energy International Development Co., Ltd. to sell Stemtech products in Taiwan, R.O.C. on October 9, 2025. The company said products are already manufactured in Taiwan and will be distributed through the licensee's retail networks. Management described the licensing model as a way to generate revenue via licensing fees and manufacturing without the costs of direct operations, while the licensee projects strong growth in the territory.
The announcement emphasizes market expansion, local manufacturing and a low‑overhead licensing strategy to monetize Stemtech's stem cell nutrition products in Taiwan.
Stemtech Corporation (OTC: STEK) ha annunciato un accordo esclusivo di licenza di distribuzione con Energy International Development Co., Ltd. per vendere i prodotti Stemtech in Taiwan, ROC il 9 ottobre 2025. L'azienda ha detto che i prodotti sono già fabbricati a Taiwan e verranno distribuiti attraverso le reti al dettaglio del licenziatario. La direzione ha descritto il modello di licenza come un modo per generare entrate tramite le tariffe di licenza e la produzione, senza i costi delle operazioni dirette, mentre il licenziatario prevede una forte crescita nel territorio.
L'annuncio enfatizza l'espansione del mercato, la produzione locale e una strategia di licenza a basso overhead per monetizzare i prodotti nutrizionali a base di cellule staminali di Stemtech a Taiwan.
Stemtech Corporation (OTC: STEK) anunció un acuerdo exclusivo de licencia de distribución con Energy International Development Co., Ltd. para vender productos de Stemtech en Taiwán, ROC el 9 de octubre de 2025. La empresa señaló que los productos ya están fabricados en Taiwán y se distribuirán a través de las redes minoristas del licenciatario. La dirección describió el modelo de licencia como una forma de generar ingresos mediante tarifas de licencia y fabricación, sin los costos de operaciones directas, mientras que el licenciatario proyecta un fuerte crecimiento en el territorio.
El anuncio enfatiza la expansión del mercado, la fabricación local y una estrategia de licencia de bajo costo para monetizar los productos de nutrición con células madre de Stemtech en Taiwán.
Stemtech Corporation (OTC: STEK)는 Energy International Development Co., Ltd.와 독점 유통 라이선스 계약을 체결했다고 2025년 10월 9일 발표했습니다. Taiwan, R.O.C.에서 Stemtech 제품을 판매하기 위한 것입니다. 회사는 이미 대만에서 제품이 생산되고 있으며 라이선시의 소매 네트워크를 통해 유통될 것이라고 말했습니다. 경영진은 라이선스 모델을 라이선스 수수료 및 제조를 통해 수익을 창출하고 직영 운영 비용은 들지 않는 방법으로 설명했고, 라이선시는 이 지역에서 강력한 성장을 예상합니다.
발표는 대만에서 Stemtech의 줄기세포 영양 보충제의 시장 확장, 현지 생산 및 저비용의 라이선스 전략을 강조합니다.
Stemtech Corporation (OTC: STEK) a annoncé un accord exclusif de licence de distribution avec Energy International Development Co., Ltd. pour vendre les produits Stemtech à Taiwan, R.O.C. le 9 octobre 2025. L'entreprise a déclaré que les produits sont déjà fabriqués à Taiwan et seront distribués par le biais des réseaux de détail du licencié. La direction a décrit le modèle de licence comme un moyen de générer des revenus via des frais de licence et la fabrication sans les coûts des opérations directes, tandis que le licencié prévoit une forte croissance sur le territoire.
L'annonce met en avant l'expansion du marché, la fabrication locale et une stratégie de licence à faible overhead pour monétiser les produits nutritionnels à base de cellules souches de Stemtech à Taiwan.
Stemtech Corporation (OTC: STEK) kündigte eine exklusive Vertriebs-Lizenzvereinbarung mit Energy International Development Co., Ltd. an, um Stemtech-Produkte in Taiwan, R.O.C. am 9. Oktober 2025 zu verkaufen. Das Unternehmen sagte, dass die Produkte bereits in Taiwan hergestellt werden und über das Einzelhandelsnetz des Lizenznehmers vertrieben werden. Das Management beschrieb das Lizenzmodell als Weg, Einnahmen über Lizenzgebühren und Fertigung zu generieren, ohne Kosten regulärer Direktgeschäfte, während der Lizenznehmer starkes Wachstum im Gebiet prognostiziert.
Die Ankündigung betont Markterweiterung, lokale Fertigung und eine Low-Overhead-Lizenzstrategie, um Stemtechs Stammzell-Nahrungsergänzungsmittel in Taiwan zu monetarisieren.
Stemtech Corporation (OTC: STEK) أعلنت عن اتفاقية ترخيص توزيع حصرية مع Energy International Development Co., Ltd. لبيع منتجات Stemtech في تايوان، جمهورية الصين تايوان (ROC) في 9 أكتوبر 2025. وقالت الشركة إن المنتجات مصنعة بالفعل في تايوان وسيتم توزيعها عبر شبكات التجزئة التابعة للمرخّص له. وصفت الإدارة نموذج الترخيص بأنه وسيلة لتوليد الإيرادات من خلال رسوم الترخيص والتصنيع دون تكاليف التشغيل المباشرة، بينما يتوقع المرخّص له نموًا قويًا في المنطقة.
التأكيد يلفت الانتباه إلى توسيع السوق، والتصنيع المحلي، واستراتيجية الترخيص منخفضة التكاليف لاستغلال منتجات Stemtech الغذائية المعتمدة على الخلايا الجذعية في تايوان.
Stemtech Corporation (OTC: STEK) 宣布与 Energy International Development Co., Ltd. 签署独家分销许可协议，在 台湾，中华民国 销售 Stemtech 产品，日期为 2025 年 10 月 9 日。公司表示产品已在台湾生产，将通过被许可方的零售网络进行分销。管理层将该许可模式描述为通过许可费和制造来创造收入，而无需直接运营成本，同时被许可方预计该地区将实现强劲增长。
公告强调市场扩张、本地制造以及以低运营成本的许可策略在台湾实现 Stemtech 的干细胞营养产品的商业化。
- Exclusive Taiwan distribution agreement signed on Oct 9, 2025
- Products already manufactured in Taiwan, supporting local supply
- Licensing model designed to generate revenue with lower overhead
- No financial terms, revenue targets, or guidance disclosed
- Concentration risk from reliance on a single Taiwan licensee
- Health and anti‑aging claims are promotional and unquantified
NAPLES, FL, AL / ACCESS Newswire / October 9, 2025 / Stemtech Corporation, the global leader and pioneer in stem cell nutrition, is proud to announce an exclusive distribution agreement with Energy International Development Co., Ltd. to sell Stemtech products in Taiwan, R.O.C.
The Taiwan Market
Stemtech Corporation Chairman & CEO, Charles S. Arnold, states "Taiwan has previously been a significant market for us. We feel with Energy International Development Co. Ltd. this will be a great source of revenue in this very large market needing the benefits of stem cell nutrition products. We look forward to our partnership with Teresa Liu, CEO, and her team in Energy International Development Co., Ltd who project exponential growth in taking over the marketing and distribution of Stemtech products ."
Teresa Liu, CEO says "the partnership with Stemtech Corporation in Taiwan will add to the improved health and wellness of many people already familiar with the great Stemtech products without needing any medical procedure but naturally releasing the body's own stem cells, allowing the body to heal itself and slow down the human aging process. Taiwan citizens are all concerned about finding natural solutions to health and aging. Stemtech meets the solution for both of these issues.
John W. Meyer, President & COO of Stemtech Corporation, advises "the agreement with Energy International Development Co., Ltd. is a tremendous growth opportunity providing distribution of all Stemtech products in the Asian market, starting in Taiwan. Our products are already manufactured in Taiwan. They will be distributed by Energy International Development Co, Ltd. and their extensive network of retail markets and other specific channels. Taiwan represents an important territory which will benefit with our products for Taiwan consumers with improved health, quality of life and anti-aging."
This model of licensing the Stemtech products into new global markets enables the Company to provide the anti-aging, longevity wellness phenomenon without the costs and overhead of running the business. This new model provides Stemtech the ability to generate revenue via licensing fees and manufacturing and enables the licensee to distribute in their territory providing Stemtech with substantial revenue without the cost of operation.
ABOUT STEMTECH
Stemtech Corporation, a leading stemceutical™ company with a direct sales distribution model, was founded on April 18, 2018, after acquiring the operations from its predecessor Stemtech International, Inc., which was established in 2005. From 2010 through 2015, Stemtech International, Inc., was recognized four separate times on the Inc. 5000 Fastest-Growing Companies list. In 2018, Stemtech underwent an extensive executive reorganization, and continued operations under new leadership as Stemtech Corporation. In August 2021, Stemtech became a publicly traded company (STEK) and has expanded business opportunities for its Independent Business Partners (IBPs), who may earn incomes by sharing Stemtech products. Stemtech is well positioned as the pioneer in stem cell nutrition, oral, skin care and soon pet health products, to increase sales in the wellness industry.
Stemtech's comprehensive product portfolio reflects its dedication to optimal health. Our all-natural innovations like stemrelease3™ (release of the adult stem cells from the bone marrow), StemFlo™ Advanced (circulation of the stem cells through the bloodstream), MigraStem® (migration from the blood stream into the area need support), and OraStem® Toothpaste (whitening teeth, freshening breath, anti-microbial, promoting good gum health) demonstrate the company's unwavering commitment to quality-of-life products and natural effectiveness. The recent launch of Cellect One® Shield: HOCL-a multipurpose mist for skin care, cleaning, and disinfecting-and its integration with the Cellect One® Rapid Renew Stem Cell Peptide Night Cream (featuring the patented QXP ingredient) underscore Stemtech's innovative edge in the beauty, health and wellness industry.
Stemtech introduced StemPets™ in June 2025 - a nutritional supplement designed for both dogs and cats. Tapping into the booming global pet wellness market, currently valued at over
For 20 years, Stemtech has not only championed the benefits of natural, plant-based ingredients but has also led the way in scientific innovation within the wellness, anti-aging, and longevity sectors. As industry forecasts and studies from reputable sources like the Global Wellness Institute project unprecedented growth, Stemtech's unwavering commitment to quality and innovation ensures that they will remain at the forefront of this transformative journey-making everyone healthier, while slowing down the aging process naturally.
ABOUT ENERGY INTERNATIONAL DEVELOPMENT CO., LTD.
Energy International Development Co., Ltd. is a dynamic business platform specializing in the distribution of high-quality, science-backed wellness and biotechnology products. a strong marketing team and a strategic growth network across Asia, Energy International serves as a trusted commercial bridge between innovative brands and rapidly expanding consumer markets. The company focuses on introducing advanced technologies and premium products that enhance health, beauty, and vitality - aligning global innovation with local cultural understanding.
Guided by a vision to create prosperity through wellness, Energy International Development Co., Ltd. integrates strategic marketing, education, and digital commerce to build sustainable value for its partners and customers alike.
FORWARD LOOKING STATEMENTS
This announcement contains forward-looking statements within the meaning of the "safe harbor" provisions of the U.S. Private Securities Litigation Reform Act of 1995. Such statements include, but are not limited to, those identified by words such as "believes," "will," "expects," "anticipates," "estimates," "intends," "plans," "targets," "projects" and similar expressions. The statements in this release are based upon the current beliefs and expectations of our company's management and are subject to significant risks and uncertainties. Actual results may differ from those set forth in these forward-looking statements. Numerous factors could cause or contribute to such differences, including, but not limited to, the results of clinical trials and/or other studies, the challenges inherent in new product development initiatives, the impact of any competitive products, our ability to license and protect our intellectual property, our ability to raise additional capital in the future, changes in government policy and/or regulation, potential litigation by or against us, any governmental review of our products or practices, and other risks discussed from time to time in our filings with the Securities and Exchange Commission. We undertake no obligation to update any forward-looking statements, or any information contained in this press release or in other public disclosures, at any time. Finally, the investing public is reminded that only announcements or information about Stemtech Corporation disseminated by the Company and bearing its name are considered official.
For Investor Relations Information Contact:
CEO Charles S. Arnold
Email: callcharlesarnold@gmail.com
Phone: +1 336-918-0507
Stemtech Corporation
Phone: +1 954-715-6000 ext 1040
Email: invrel@stemtech.com
Energy International Development Co., Ltd.
CEO Teresa Liu
Phone: +886 424716066
Email: teresa1977.liu@gmail.com
SOURCE: Stemtech Corporation
View the original press release on ACCESS Newswire
FAQ
What did Stemtech (STEK) announce on October 9, 2025 regarding Taiwan?
How will the Taiwan agreement affect Stemtech's revenue model (STEK)?
Are there disclosed financial terms or revenue targets for STEK's Taiwan deal?
Will Stemtech manufacture products for Taiwan locally under the STEK agreement?
What risks should investors consider about Stemtech's Taiwan license (STEK)?
Does the Taiwan agreement include guarantees of sales or clinical proof for STEK products?
